QualityStocksNewsBreaks Archives - Page 977 of 1576

WednesdayNov 25, 2020 1:15 pm

QualityStocksNewsBreaks – Exro Technologies Inc. (TSX.V: EXRO) (OTCQB: EXROF) CEO Featured in TMX Group Video Interview Series

Canadian-based Exro Technologies (TSX.V: EXRO) (OTCQB: EXROF), a company commercializing patented technology designed to advance existing rotating electric machines, on Tuesday announced that its chief executive officer Sue Ozdemir was featured in a newly released interview with TMX Group. During the interview, Ozdemir talks about the company’s history and current focus and commitment. The interview is part of TMX’s “The C-Suite at The Open” video interview series, which provides insight into how company executives think in the current business environment. To view the full interview, visit https://ibn.fm/tr7nw To view the full press release, visit https://ibn.fm/zM8io About Exro Technologies Inc. Exro is a clean-tech…

WednesdayNov 25, 2020 12:25 pm

QualityStocksNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Provide Digital Therapeutics Solution to Employees of Fortune 500 Company

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, will be providing its digital therapeutics solution to qualified employees of a U.S.-based Fortune 500 technology company. The contract, which goes into effect on Jan. 1, 2021, with the beginning of a new benefits year, calls for Dario to provide its digital diabetes tools and coaching to employees and their dependents. “We believe that employees will benefit from Dario's unique therapeutic approach, which delivers adaptive, personalized experiences designed to drive behavior change through intuitive, clinically proven digital tools and coaching,” said DarioHealth president and North America GM Rick Anderson…

WednesdayNov 25, 2020 11:33 am

QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Announces Executive Leadership Changes

Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) has announced that its executive leadership team will be changing; these changes follow last month’s naming of a new CEO and board chair along with a new vice chair. As a result of this week’s changes, the company is actively looking for new key executives, including a chief financial officer, chief general counsel and senior vice president of investor and public communications. The company also plans to announce additional board members coming from key business and science segments. Current board members who are remaining include Dr. Roger McIntyre, chair and CEO; Bill Wilkerson, vice…

WednesdayNov 25, 2020 10:31 am

QualityStocksNewsBreaks – Knightscope Inc. Announces Continued Engagement of InvestorBrandNetwork, Interview with LD Micro

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”), on Tuesday announced it will continue to utilize the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. As part of the client-partner relationship, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Knightscope. “Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of…

TuesdayNov 24, 2020 3:37 pm

QualityStocksNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Initiates Clinical Evaluation of CaniSun(TM)

Jupiter Wellness (NASDAQ: JUPW), a developer of cannabidiol (“CBD”) based therapeutics and wellness products, today announced initiation of a clinical study of its CaniSun(TM) sunscreen lotion for the treatment of actinic keratosis (“AK”), the most common precancer that forms on the skin as a result of exposure to ultraviolet (“UV”) rays. The clinical study’s primary objective is to evaluate Canisun as a treatment for AK by reviewing the efficacy in both treatment and prophylaxis of patients. The study, to be conducted by Applied Biology (Irvine, California), will recruit an estimated 116 adults diagnosed with AK. “I am excited to work…

TuesdayNov 24, 2020 3:20 pm

QualityStocksNewsBreaks – ev Transportation Services Inc. (‘evTS’) Engages InvestorBrandNetwork for Corporate Communications Expertise

ev Transportation Services (“evTS”), a specialty vehicle OEM, today announced it has selected the corporate communications expertise of the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. Under the partnership, IBN will leverage its investor-based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for evTS. “The essential services vehicle fleet represents an annual domestic replacement market of approximately 100,000 vehicles. These vehicles roughly translate to a $2.5 billion market opportunity each year,” said Chris Johnson, director of…

TuesdayNov 24, 2020 3:16 pm

QualityStocksNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Ring Nasdaq Opening Bell

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that, in celebration of its recently completed initial public offering, it will ring the Nasdaq Stock Exchange opening bell on November 27, 2020. 180 Life Sciences CEO Dr. James Woody will be joined by members of the ATNF team for the virtual ceremony, which will begin at approximately 9:20 a.m. Eastern Time, and can be viewed live at https://ibn.fm/R4bwK, as well as on the…

TuesdayNov 24, 2020 2:45 pm

QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Korea Biomedical Review Article

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a recent article published in the Korea Biomedical Review. The piece, titled “Yuhan emerges as global new-drug developer with $3.6 billion tech export,” discusses Yuhan Corp.’s (OCT: YUHNF) move to enter technology transfer deals with global pharmaceutical companies, including Janssen Biotech, Gilead Sciences Inc. (NASDAQ: GILD), Boehringer Ingelheim and Processa. The article reads, “Yuhan also made a $410.5 million contract with the U.S. Processa Pharmaceuticals in 2020 for transferring the technology of…

TuesdayNov 24, 2020 2:08 pm

QualityStocksNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Begins Strategic Greater Bay Area Expansion

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality ("AR") interactive entertainment games, toys and educational materials in China, today announced its entry into an agreement with three preschools (the First and Fourth Preschools and the Children's Center) of Guangzhou Development District Talent Work Group of Augmented Reality Immersive Classes (“ARIC”). According to the update, the move marks the beginning of Blue Hat's strategic expansion in the Guangdong -Hong Kong-Macao Greater Bay Area (the “Greater Bay Area”). “I am pleased with Blue Hat's cooperation with three preschools in Guangzhou. At present, we have…

TuesdayNov 24, 2020 1:49 pm

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Stock2Me Podcast

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in InvestorBrandNetwork’s (“IBN”) latest episode of its Stock2Me Podcast. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are revolutionizing business practices within their respective markets. AZRX president and CEO James Sapirstein joins IBN’s Stuart Smith in the latest episode to discuss how AzurRx is working to redefine the standard of care for patients living with cystic fibrosis and chronic pancreatitis. “AzurRx Bio has been around for five years. … Our main product, MS1819, is being studied in…

Site Search

Company Search

Category: QualityStocksNewsBreaks